Choose Language: RU / EN

Clinical studies

The first clinical studies were conducted in 1978 in seven clinical centers (Moscow Research Institute of Psychiatry, Institute of General and Forensic Psychiatry n.a. V.P. Serbsky, Department of Nervous Diseases, the Medical Faculty of the MSUMD n.a. N. A. Semashko, Department of Nervous Diseases, 1 medical faculty of the 1MMI, NR Leningrad neuropsychiatric Institute n.a. V.M. Bekhterev, Institute of Clinical and Experimental Neurology of MOH Gr.SSR, Kharkov Institute of Neurology and Psychiatry n.a. V.P. Protopopova). The study involved 503 patients with epilepsy and epileptiform syndrome of different genesis. Clinical studies have shown the high efficiency of Galodif, which has a broad spectrum of antiepileptic action.

During the application a positive therapeutic effect is expressed by the termination or reduction of attacks (more than 50%), this was observed in 81.9% of cases (412 patients out of 503). At the same time for many patients the clinical effect was accompanied by a normalization or improvement of electrobiological brain activity. Therapeutic activity of Galodif was shown both in terms of large convulsive seizures and focal seizures with simple symptoms, temporal, secondarily generalized and their various combinations. Clinical effect in the above-mentioned forms noted in 84.7-93,5% of patients.

When alcoholic epilepsy Galodif tends to prevent the development of alcoholic mania and it tends to stop it in the short term (up to 3 days). Also dehydrating properties of the drug were noticed, which is a significant addition to its antiepileptic effect. The drug has low toxicity and high tolerability without causing complications. During the study of Galodif on a model Galodifa alcohol addiction showed that the drug possesses anticonvulsant, analgesic and sedative effects. Also dehydrating properties of the drug were marked, which is a significant addition to its antiepileptic effect. The drug has low toxicity and good tolerance without causing complications. During the study of Galodif by the model of alcohol addiction we discovered that the drug has anticonvulsant, analgesic and sedative effects.

Galodif can be attributed to drugs with anti-craving effect, normalizing catecholamine neuromediation in order to reduce the morbid tendency to alcohol and failure prevention. The usage of Galodif is effective when patients with complicated forms of alcoholism have remission when the primary pathological attraction to ethanol arises spontaneously. The drug has the following properties: nootropic, dehydrating and antihypoxic effect.